Works matching DE "SEMAGLUTIDE"

Results: 546

Impact of Semaglutide Administration on Weight Loss After Bariatric Surgery: A Meta-Analysis.

Published in:

Obesity Surgery, 2025, v. 35, n. 7, p. 2490, doi. 10.1007/s11695-025-07848-y

By:

Jamialahamdi, Tannaz;
Mirhadi, Elaheh;
Almahmeed, Wael;
Virani, Salim;
Eid, Ali H.;
Al-Rasadi, Khalid;
Salehabadi, Sepideh;
Sahebkar, Amirhossein

Publication type:

Article

Letter: Amiodarone-Induced Thyrotoxicosis Following Semaglutide-Associated Weight Loss.

Published in:

2025

By:

Giordani, Ilaria;
Sykiotis, Gerasimos P.

Publication type:

Letter

Summary for Patients: Semaglutide or Dulaglutide Versus Empagliflozin for Risk for Death and Cardiovascular Outcomes Among Patients With Type 2 Diabetes.

Published in:: Annals of Internal Medicine, 2025, v. 178, n. 7, p. I-10, doi. 10.7326/ANNALS-24-00775-PS
Publication type:: Article

Comparison of Semaglutide or Dulaglutide Versus Empagliflozin for Risk for Death and Cardiovascular Outcomes Among Patients With Type 2 Diabetes: Two Target Trial Emulation Studies.

Published in:

Annals of Internal Medicine, 2025, v. 178, n. 7, p. 930, doi. 10.7326/ANNALS-24-00775

By:

Saeed, Anum;
Mulukutla, Suresh R.;
Thoma, Floyd;
Lemon, Lara;
Koczo, Agnes;
Reis, Steven;
Marroquin, Oscar;
Kip, Kevin

Publication type:

Article

Tirzepatide Outperforms Semaglutide in Head-to-Head Obesity Trial.

Published in:

JAMA: Journal of the American Medical Association, 2025, v. 334, n. 2, p. 107, doi. 10.1001/jama.2025.7798

By:

Anderer, Samantha

Publication type:

Article

Semaglutide Improves Lipid Subfraction Profiles in Type 2 Diabetes: Insights from a One-Year Follow-Up Study.

Published in:

International Journal of Molecular Sciences, 2025, v. 26, n. 13, p. 5951, doi. 10.3390/ijms26135951

By:

Tóth, László Imre;
Harsányi, Adrienn;
Csiha, Sára;
Molnár, Ágnes;
Lőrincz, Hajnalka;
Nagy, Attila Csaba;
Paragh, György;
Harangi, Mariann;
Sztanek, Ferenc

Publication type:

Article

Effect of Four-Week Semaglutide Therapy and Its Combination with Intranasal Insulin on Thyroid and Gonadal Status in Male Rats with Type 2 Diabetes.

Published in:

Journal of Evolutionary Biochemistry & Physiology, 2025, v. 61, n. 3, p. 751, doi. 10.1134/S002209302503007X

By:

Derkach, K. V.;
Zorina, I. I.;
Fedorchuk, I. V.;
Shpakov, A. O.

Publication type:

Article

Semaglutide Adverse Events Named in Nearly 25,000 ED Visits in 2 Years Since Approval.

Published in:

Healio Gastroenterology, 2025, v. 11, n. 6, p. 19

By:

Kellner, Sara

Publication type:

Article

FDA Accepts Application for Oral Version of Wegovy.

Published in:

JAMA: Journal of the American Medical Association, 2025, v. 334, n. 1, p. 12, doi. 10.1001/jama.2025.7761

By:

Anderer, Samantha

Publication type:

Article

Glucagon‐like peptide‐1 receptor agonists and alcohol use disorders: An emerging unexpected beneficial effect.

Published in:

Diabetes, Obesity & Metabolism, 2025, v. 27, n. 8, p. 4083, doi. 10.1111/dom.16453

By:

Scheen, André J.

Publication type:

Article

Incretin mimetics for weight loss forgive nonadherence.

Published in:

Diabetes, Obesity & Metabolism, 2025, v. 27, n. 8, p. 4109, doi. 10.1111/dom.16438

By:

Cengiz, Anıl;
Wu, Calvin C.;
Lawley, Sean D.

Publication type:

Article

Semaglutide ameliorates diabetes-associated cognitive dysfunction in mouse model of type 2 diabetes.

Published in:

PLoS ONE, 2025, v. 20, n. 7, p. 1, doi. 10.1371/journal.pone.0326897

By:

Zhu, Yan;
He, Yi;
Yang, Hongyan;
Gao, Yanbo;
Wang, Yan;
Liu, Peiqing;
Zhang, Mengjuan

Publication type:

Article

COMBINE 2 is better than one: shaping the future of therapeutics in inadequately controlled type 2 diabetes.

Published in:

Expert Review of Clinical Pharmacology, 2025, v. 18, n. 5, p. 259, doi. 10.1080/17512433.2025.2516784

By:

Popovic, Djordje S.;
Patoulias, Dimitrios;
Koufakis, Theocharis;
Papanas, Nikolaos

Publication type:

Article

Uptake of and Disparities in Semaglutide and Tirzepatide Prescribing for Obesity in the US.

Published in:

JAMA: Journal of the American Medical Association, 2025, v. 333, n. 24, p. 2203, doi. 10.1001/jama.2025.4735

By:

Kim, Chungsoo;
Ross, Joseph S.;
Jastreboff, Ania M.;
Meeker, Daniella;
Freedman, Harry;
Krumholz, Harlan M.;
Lu, Yuan

Publication type:

Article

Use of incretin-based therapies in women using hormone replacement therapy (HRT).

Published in:

Post Reproductive Health, 2025, v. 31, n. 2, p. 127, doi. 10.1177/20533691251343069

By:

Mukherjee, Annice;
Ghaem-Maghami, Sadaf;
Syed, Akheel A

Publication type:

Article

Titration and discontinuation of semaglutide for weight management in commercially insured US adults.

Published in:

Obesity (19307381), 2025, v. 33, n. 7, p. 1243, doi. 10.1002/oby.24315

By:

Xu, Yunwen;
Carrero, Juan J.;
Chang, Alexander R.;
Inker, Lesley A.;
Zhang, Donglan;
Mukhopadhyay, Amrita;
Blecker, Saul B.;
Horwitz, Leora I.;
Grams, Morgan E.;
Shin, Jung‐Im

Publication type:

Article

The NLRP3 inhibitor NT‐0796 enhances and sustains GLP‐1R agonist‐mediated weight loss in a murine diet‐induced obesity model.

Published in:

Obesity (19307381), 2025, v. 33, n. 7, p. 1309, doi. 10.1002/oby.24305

By:

Thornton, Peter;
Reader, Valérie;
Digby, Zsofia;
Doedens, John;
Lindsay, Nicola;
Clarke, Nicholas;
Watt, Alan P.

Publication type:

Article

A GLP1R gene variant and sex influence the response to semaglutide treatment in patients with severe obesity.

Published in:

Obesity (19307381), 2025, v. 33, n. 7, p. 1237, doi. 10.1002/oby.24300

By:

Phan, Aurélie;
Carette, Claire;
Narjoz, Céline;
Rives‐Lange, Claire;
Rassy, Nathalie;
Czernichow, Sebastien;
Pallet, Nicolas

Publication type:

Article

Real-World Analysis of Short-Term Effectiveness of Oral Semaglutide: Impact on Glycometabolic Control and Cardiovascular Risk.

Published in:

Pharmaceuticals (14248247), 2025, v. 18, n. 6, p. 856, doi. 10.3390/ph18060856

By:

Palazzi, Sara;
Sentinelli, Federica;
Zugaro, Antonella;
Morgante, Sara;
Santarelli, Livia;
Melanzi, Sandra;
De Mutiis, Annamaria;
Piersanti, Deamaria;
Macerola, Barbara;
Iezzi, Marco;
Mercuri, Pietro;
Ferranti, Alessandro;
Tienforti, Daniele;
Cavallo, Maria Gisella;
Barbonetti, Arcangelo;
Baroni, Marco Giorgio

Publication type:

Article

Ozempic Approval Expanded to Include Patients with T2D and CKD: Daily Dose.

Published in:

Patient Care (Online), 2025, p. 4

By:

Jennings, Sydney

Publication type:

Article

High-Dose Semaglutide Linked to Increased Weight Loss: Daily Dose.

Published in:

Patient Care (Online), 2025, p. 3

By:

Jennings, Sydney

Publication type:

Article

FDA Approves New Indication for Semaglutide (Ozempic) to Lower Kidney Risks in Type 2 Diabetes, CKD.

Published in:

Patient Care (Online), 2025, p. 2

By:

Jennings, Sydney

Publication type:

Article

CagriSema Leads to Weight Reduction of Approximately 23% in Phase 3 REDEFINE 1 Clinical Trial, Short of the 25% Expected.

Published in:

Patient Care (Online), 2024, p. 13

By:

Halsey, Grace

Publication type:

Article

Future of Obesity Care: 3 Wishes from Thought Leader Donna Ryan, MD.

Published in:

Patient Care (Online), 2024, p. 6

By:

Ryan, Donna H.

Publication type:

Article

Tirzepatide Superior to Semaglutide in Weight Loss Trial: Daily Dose.

Published in:

Patient Care (Online), 2024, p. 7

By:

Jennings, Sydney

Publication type:

Article

Tirzepatide Bests Semaglutide for Weight Loss by 47% in Head-to-Head Trial.

Published in:

Patient Care (Online), 2024, p. 4

By:

Halsey, Grace

Publication type:

Article

Oral Semaglutide Linked to Lower Risk of MACE: Daily Dose.

Published in:

Patient Care (Online), 2024, p. 1

By:

Jennings, Sydney

Publication type:

Article

Semaglutide vs Tirzepatide for Weight Loss in Persons with Obesity: Daily Dose.

Published in:

Patient Care (Online), 2024, p. 70

By:

Jennings, Sydney

Publication type:

Article

Weight Loss with Tirzepatide Significantly Greater than with Semaglutide: New Data.

Published in:

Patient Care (Online), 2024, p. 48

By:

Halsey, Grace

Publication type:

Article

Semaglutide Sold Online without Prescription May Put Users at Risk for Fraud, Overdose.

Published in:

Patient Care (Online), 2024, p. 6

By:

Jennings, Sydney

Publication type:

Article

FLOW Trial: Semaglutide Lowers Risk for Major Kidney Disease, CV Events and Death Regardless of SGLT-2i Use.

Published in:

Patient Care (Online), 2024, p. 1

By:

Jennings, Sydney

Publication type:

Article

WHO Issues Medical Product Alert for Counterfeit Semaglutide.

Published in:

Patient Care (Online), 2024, p. 1

By:

Klein, Hayden E.

Publication type:

Article

ADA 84th Scientific Sessions: 3 Studies Primary Care Clinicians Should Put on Their Radar.

Published in:

Patient Care (Online), 2024, p. 3

By:

Jennings, Sydney

Publication type:

Article

Semaglutide Significantly Reduces Risk of Renal Events, MACE, Death in Persons with CKD, T2D: Daily Dose.

Published in:

Patient Care (Online), 2024, p. 2

By:

Jennings, Sydney

Publication type:

Article

Semaglutide Significantly Reduces Risk of Renal Events, MACE, Mortality in People with CKD, T2D in Final FLOW Trial Findings.

Published in:

Patient Care (Online), 2024, p. 1

By:

Halsey, Grace

Publication type:

Article

Semaglutide Supports Long-Term Weight Loss, Reduces CV Risk Across BMI Subgroups.

Published in:

Patient Care (Online), 2024, p. 1

By:

Halsey, Grace

Publication type:

Article

Adults with Prior Antiobesity Medication Use Before Semaglutide Use Lose More Weight: Daily Dose.

Published in:: Patient Care (Online), 2024, p. 2
Publication type:: Article

Adults with Obesity Who Receive Semaglutide as First Weight Loss Medication Lose More Weight.

Published in:

Patient Care (Online), 2024, p. 1

By:

Jennings, Sydney

Publication type:

Article

Semaglutide Improves Functional Status, Body Weight in Patients with HFpEF, Obesity, T2D: Daily Dose.

Published in:

Patient Care (Online), 2024, p. 1

By:

Jennings, Sydney

Publication type:

Article

Medicare Will Cover AOM Semaglutide for Cardiovascular Risk Reduction: A First.

Published in:

Patient Care (Online), 2024, p. 1

By:

Halsey, Grace

Publication type:

Article

Semaglutide Lowers CKD-Related Events in Persons with T2D, CKD: Daily Dose.

Published in:

Patient Care (Online), 2024, p. 1

By:

Jennings, Sydney

Publication type:

Article

Semaglutide Lowers CKD-Related Events in Persons with T2D, CKD: Daily Dose.

Published in:

Patient Care (Online), 2024, p. 2

By:

Jennings, Sydney

Publication type:

Article

Semaglutide 2.4 mg (Wegovy) Wins Expanded Indication to Include Reduced Risk of MACE.

Published in:

Patient Care (Online), 2024, p. 1

By:

Halsey, Grace

Publication type:

Article

Semaglutide Reduces CKD-Related Events by 24% in Population with T2D and CKD: FLOW Findings Announced.

Published in:

Patient Care (Online), 2024, p. 1

By:

Halsey, Grace

Publication type:

Article

Semaglutide Shows Potential for Significant CVD Prevention: Daily Dose.

Published in:

Patient Care (Online), 2024, p. 1

By:

Jennings, Sydney

Publication type:

Article

Semaglutide Reduces CKD-Related Events by 24% in Population with T2D and CKD: FLOW Findings Announced.

Published in:

Patient Care (Online), 2024, p. 1

By:

Halsey, Grace

Publication type:

Article

Semaglutide Linked to Lower Risk of Suicidal Ideation in Patients with Obesity, Type 2 Diabetes.

Published in:

Patient Care (Online), 2024, p. 3

By:

Jennings, Sydney

Publication type:

Article

Where is All the Wegovy Going?

Published in:

Patient Care (Online), 2024, p. 2

By:

Halsey, Grace

Publication type:

Article

Semaglutide Shows Potential for Significant CVD Prevention in Analysis of Real-World Data.

Published in:

Patient Care (Online), 2024, p. 1

By:

Halsey, Grace

Publication type:

Article

"Ozempic" and Older Adults: Awareness of & Views on Rx Medications for Weight Management.

Published in:

Patient Care (Online), 2024, p. 1

By:

Halsey, Grace

Publication type:

Article